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Accepted 1 September 2016Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke
and systemic embolism in patientswith atrialﬁbrillation and to prevent and treat venous thromboembolism. These
drugs reduce the risk of clotting at the expense of increasing the risk of bleeding, and currently they have no speciﬁc
reversal agent. However, andexanet alfa, a recombinantmodiﬁed FXa decoymolecule, is in a late-phase clinical trial
in bleeding patients, and ciraparantag, a small molecule that appears to reverse many anticoagulants including the
FXa inhibitors, is in development. This review summarizes the published data to date on both drugs, which have the
potential to change the management approach to patients with FXa inhibitoreassociated major hemorrhage.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Oral factor Xa (FXa) inhibitors, a class of the direct-acting oral
anticoagulants approved for prevention of stroke and systemic
embolism in nonvalvular atrial ﬁbrillation and treatment and preven-
tion of venous thromboembolism, consistently have been shown to be
noninferior to warfarin in clinical trials evaluating their safety and
efﬁcacy [1-7]. As with any anticoagulant, these drugs incrementally
increase the risk of bleeding to greatly reduce the risk of clotting
(eg, stroke and venous thromboembolism). Before the U.S. Food and
Drug Administration’s (FDA) approval of idarucizumab, a speciﬁc rever-
sal agent for the direct thrombin inhibitor dabigatran, the lack of rever-
sal agents was a consistent concern associated with the use of all direct-
acting oral anticoagulants. Currently, there is no approved speciﬁc
reversal agent for FXa inhibitors, although latephase clinical trials of re-
versal agents are ongoing [8].ngelheim Pharmaceuticals, Inc
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. This is an open access article underWarfarin anticoagulation historically has been reversed with vita-
min K1 (to reinitiate synthesis of affected factors II, VII, IX, and X,
along with proteins C and S) and fresh-frozen plasma (to replete these
factors more immediately) [9], although the effectiveness of this
approach has not been demonstrated in clinical trials. Despite being
approved for human use in the 1950s in the United States, warfarin
had no fast-acting, speciﬁc reversal agent supported by evidence from
a randomized controlled trial until 2013, when a 4-Factor prothrombin
complex concentrate (PCC) was approved [10-12]. The ﬁrst oral FXa
inhibitor, rivaroxaban, was approved in the United States in 2011 [13],
by which time reversal agents for direct-acting oral anticoagulants
were already in development. The FXa inhibitors apixaban [14] and
edoxaban [15] have since been approved, andmore are in development
(note that all FXa inhibitors have the sufﬁx “Xa-ban” [Ten-A-Ban] to de-
note their mechanism of action).
Preclinical and clinical data on 2 reversal agents, andexanet alfa
(Portola Pharmaceuticals, South San Francisco, Calif), a recombinant
modiﬁed FXa decoy molecule, and ciraparantag (PER977, Perosphere
Pharmaceuticals, Danbury, Conn), a small molecule, will be covered in
this review. Idarucizumab, a speciﬁc reversal agent to dabigatran, is cov-
ered in other chapters [16-18] of this special issue. Off-label use of factor
products, for example, PCCs or recombinant FVIIa, to treat bleeding in
patientswhohave been anticoagulatedwith direct-acting oral anticoag-
ulants is covered elsewhere [19] in this special issue.
1. Andexanet alfa
1.1. Pharmacology
Lu et al [20], from Portola, published a proof-of-concept article on
andexanet alfa in 2013, describing the molecule as a truncated form ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1















ATIII-FXa = antithrombin III factor Xa; FIIa = factor IIa; FXa = factor Xa; LMWH= low-
molecular-weight heparin; UFH = unfractionated heparin; VKA = vitamin K antagonist.
Adapted from Lu et al [20,21], Crowther et al [22], and Sullivan et al [23].
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Va (FVa) to form the prothrombinase complex, which cleaves pro-
thrombin (factor II [FII]) to thrombin (factor IIa [FIIa]), which in
turn cleaves ﬁbrinogen to ﬁbrin. Two elegant modiﬁcations were
made to native human FXa to create andexanet (Fig. 1). First, the substi-
tution of a serine residue with an alanine at the active site eliminates
the protein’s catalytic activity, that is, its ability to cleave prothrombin
to thrombin. Second, the removal of the Gla (carboxyglutamic acid)
domain eliminates its ability to assemble into the prothrombinase
complex, thus removing any anticoagulant effect through the preven-
tion of binding native FVa and inhibiting prothrombin activation.
The molecule retains its ability to bind direct FXa inhibitors (the
Xabans), but it also binds to low-molecular-weight heparins (LMWH),
pentasaccharide-activated antithrombin III (ATIII), and unfractionated
heparin, and thereby alters the activity of these indirect FXa inhibitors
(Table 1) [20,21]. Investigators recently reported robust double-blind,
placebo-controlled safety and biomarker reversal data on nonbleeding
older volunteers [24]. A summary of the preclinical and clinical studies
of andexanet is shown in Table 2 and discussed in further detail in
this review.
1.2. Preclinical animal studies and human blood in vitro studies
The seminal article by Lu et al [20] demonstrated a rapid effect of
andexanet, which appeared to reverse direct FXa inhibitors completely
in human and rat plasma and to restore hemostasis and reduce bleeding
in mouse tail transection and rabbit liver laceration models. In humans,
andexanet has an effective half-life of approximately 1 hour, which
depends on the dose of andexanet and the particular FXa inhibitor
with which it is used [24]. The FDA granted Portola breakthrough
therapy designation, intended to expedite the development and
review of drugs for serious or life-threatening conditions, for andexanet
in 2013 [33].
Beyond the primary effect of reestablishing hemostatic efﬁcacy,
there are 2 major safety concerns, one general to all anticoagulant “re-
versal” agents and one speciﬁc to the andexanet approach, neither of
which has been demonstrated despite ongoing surveillance. Generally,
reversal agentsmust effectively restore hemostasiswithout creating ex-
cessive rebound hypercoagulable states and risk for clinically signiﬁcant
thromboembolic events. Speciﬁc to andexanet alfa, a modiﬁed clotting
factor must not lead to an antibody response against its native cousin,
potentially causing an iatrogenic clotting factor deﬁciency.
1.3. Clinical studies
In a phase 2 dose-ranging, proof-of-concept study in healthy,
nonbleeding volunteers treated with apixaban, rivaroxaban, the
LMWH enoxaparin [22], or edoxaban [32], andexanet demonstrated
rapid (within 2 minutes) [34,35] reversal of anticoagulation activity,
as measured by anti-FXa activity assays; anti-FXa activity returned to
placebo levels in approximately 2 hours after treatment in the study
of reversal of edoxaban-induced anticoagulation [32]. The reversal
could be extended with a continuous infusion [22]. There were noFig. 1.Design of andexanet alfa. Serine, the active site of FXa, was substitutedwith alanine, rend
removed to prevent its assembly into the prothrombinase complex, thus removing any anticoag
Portola Pharmaceuticals, Inc (South San Francisco, Calif).observed thrombotic events, serious adverse events, discontinuation
because of adverse events, or antibodies to endogenous human FXa or
FX [22,32].
Andexanet has since been studied in phase 3, double-blind, placebo-
controlled studies as a single bolus or a bolus plus 2-hour infusion in
nonbleeding healthy older adults (50-75 years) treated with apixaban
or rivaroxaban [24]. Andexanet was administered as a bolus plus 2-
hour infusion because the half-life of the drug is approximately 1 hour
(Fig. 2). The apixaban and rivaroxaban groups were administered 400
or 800 mg of andexanet, respectively; doses were selected on the
basis of the stoichiometric ratio needed for the reversal of each antico-
agulant. In the apixaban group, anti-FXa activity was reduced by 94%
in subjects (n = 24) who received an andexanet bolus versus 21% in
participants (n = 9) who received placebo (P b .001), and the concen-
tration of unbound apixaban was reduced by 9.3 ng/mL versus 1.9
ng/mL (P b .001); thrombin generation was fully restored within 2 to
5 minutes in 100% versus 11% of subjects (P b .001) (Fig. 2A) [24]. In
the rivaroxaban group, anti-FXa activity was reduced by 92% in subjects
(n= 27) who received an andexanet bolus versus 18% in subjects (n=
14) who received placebo (P b .001), and the concentration of unbound
rivaroxaban was reduced by 23.4 ng/mL versus 4.2 ng/mL (P b .001);
thrombin generation was fully restored in 96% versus 7% of subjects
(P b .001) (Fig. 2B) [24]. When andexanet was administered as a bolus
plus 2-hour infusion, these effects were sustained in subjects treated
with apixaban and rivaroxaban (Fig. 2C and D). Transient increases in
levels of D-dimer and prothrombin fragments 1 and 2 (F1.2) occurred
in a subgroup of subjects, raising a concern for prothrombotic effect,
but this normalized within 24 to 72 hours [24]. Mild infusion re-
actions were reported in some subjects, and 1 subject developed
hives [24]. Subjects were followed for 6 weeks, and there were no seri-
ous adverse events, thromboembolic events, or neutralizing antibody
development [24].
The pivotal Andexanet Alfa a Novel Antidote to the Anticoagulant Ef-
fects of FXa Inhibitors (ANNEXA)-4 trial (NCT02329327) [36] is nowering themolecule unable to cleave and activate prothrombin. The Gla domain of FXa was
ulant effects. Gla= gamma-carboxyglutamic acid-rich. Reproducedwith permission from
Table 2
Summary of Preclinical and Clinical Studies of Andexanet.
Enoxaparin Dabigatran Rivaroxaban Apixaban Edoxaban
Animal in vivo
Rat tail transection Decreased bleeding by
N50% [25]
– – – –
Mouse tail transection – – Decreased bleeding by N80%
(+ ASA) [26]
–
Rabbit liver laceration – – Decreased bleeding by N80% [27] –
Human in vitro – – Dose-dependent reversal of
anti-FXa activity in a buffer
system of puriﬁed human FXa;
reversal of direct and
ATIII-dependent FXa inhibitors in
human plasma [28]
Dose-dependent reversal of
anti-FXa activity in a buffer
system of puriﬁed human FXa;
reversal of direct and
ATIII-dependent FXa inhibitors in
human plasma [28]
Dose-dependent reversal of
anti-FXa activity in a buffer
system of puriﬁed human FXa;
reversal of direct and
ATIII-dependent FXa inhibitors in
human plasma [28]
Anti-FXa activity of exogenous
rivaroxaban was reduced in
human plasma from healthy
subjects pre-treated with
andexanet [29]
Human in vivo Reversal of anti-FXa
activity in healthy
subjects [22]
– Reversal of anti-FXa activity in
healthy subjects [22]
Dose-dependent reversal of
anti-FXa activity in healthy
subjects and partial restoration of
thrombin generation and partial
reversal of prolongation of
clotting time [30]
Sustained reversal of anti-FXa
activity with bolus plus infusion in
healthy older subjects [24]
Reversal of anti-FXa activity in
healthy subjects [22]
Sustained reversal of anti-FXa
activity with bolus plus infusion in
healthy subjects [31]
Sustained reversal of anti-FXa
activity with bolus plus infusion in
healthy older subjects [24]
Dose-dependent reversal of
anti-FXa activity in healthy subjects
and restoration of thrombin
generation and reversal of
prolongation of clotting time [32].
ASA = acetylsalicylic acid; ATIII = antithrombin III; FXa = factor Xa.
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study andexanet in bleeding humans and shares some similarities with
the trials of the 4-Factor PCC for warfarin reversal [10,11]. One major
difference is the lack of a control group (eg, plasma in the 4-Factor
PCC trials). Because there is no standard of care for reversing these
drugs, and thus no reasonable active control, it would not be ethical or
feasible to give placebos to patients with major hemorrhages. The
same reasoning accounts for the single-arm design in the idarucizumab
study, REVERSal Effects of Idarucizumab on Active Dabigatran (RE-
VERSE AD) [37]. One of the ANNEXA-4 study’s primary outcomes is clin-
ical hemostatic efﬁcacy [36] similar to a scale developed for the 4-Factor
PCC trials [10], and safety outcomes also are being gathered. The trial
may take several years to enroll its cohort, but given its FDA break-
through designation, the drug could be approved before completion,
as was the case with idarucizumab.
It is worth noting that there are some key differences between the
ANNEXA-4 study [36] and the study of idarucizumab for the reversal
of dabigatran in the REVERSal Effects of Idarucizumab in Patients on Ac-
tive Dabigatran (RE-VERSE AD) trial [37]. The ANNEXA-4 study strictly
requires that subjects meet major hemorrhage criteria for inclusion,
and it excludes participation in the efﬁcacy analysis if patients do not
meet these criteria [36]. Therefore, a strength of the ANNEXA-4 study
is that it includes patients with well-characterized major hemorrhage
who are in need of immediate reversal [36]. In contrast, RE-VERSE AD
was more permissive, allowing physician discretion on who required
immediate reversal therapy and thus was designed to mimic a “real-
world” population [37]. In addition, the primary end point of the RE-
VERSE AD study was the percentage reversal of the anticoagulant effect
of dabigatran. This calculation included the measurements of dilute
thrombin time or ecarin clotting time, both of which correlate consis-
tently with the concentration of unbound dabigatran across a wide
range of dabigatran concentrations. The ANNEXA-4 study uses dual pri-
mary outcomes of a biomarker (anti-FXa levels) plus a clinical outcome
of hemostatic efﬁcacy [36,38].2. Ciraparantag
2.1. Pharmacology
Perosphere is developing ciraparantag (di-arginine piperazine; for-
merly known as “aripazine” or “PER977”). Ciraparantag is a small (512
Da) synthetic molecule that reportedly binds to unfractionated heparin,
LMWH fondaparinux, and the direct-acting oral anticoagulants
dabigatran, rivaroxaban, apixaban, and edoxaban [23,39,40] (Table 1).
It inactivates anticoagulants via noncovalent hydrogen binding, which
blocks the binding to the target sites of FIIa and FXa. It does not
bind to coagulation factors or other plasma proteins [23,41,42] and
has no measurable prothrombotic effect as measured by D-dimer,
F1.2, or tissue factor pathway inhibitor [43]. The chemical structure of
ciraparantag is shown in Fig. 3. A summary of the preclinical and clinical
studies of ciraparantag is shown in Table 3 and discussed in further de-
tail in this review.
2.2. Preclinical animal studies
Laboratory rats were dosed with edoxaban and followed by
ciraparantag or saline in 3 models: tail transection, liver laceration,
and measurement of whole blood clotting time. Ciraparantag de-
creased bleeding within 7.5 minutes in the tail transection model,
within 10 minutes in the liver laceration model [45], and within 30
minutes in the whole blood clotting time model [46]. Ciraparantag
also has been shown to reduce bleeding from tail transection by
more than 90% in rats overdosed with dabigatran, rivaroxaban, or
apixaban [39].
Andexanetmanufacturer Portola synthesized ciraparantag and com-
pared the reversal effects in a rabbit liver laceration model with prior
studies with andexanet [47]. High-dose ciraparantag reversed blood
loss to a similar extent as andexanet. In nonanticoagulated rabbits,
there was a reduction in blood loss suggesting ciraparantag may have
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Fig. 2. Time courses of plasma concentrations of unbound apixaban or rivaroxaban before and after administration of andexanet. Concentrations of unbound apixaban or rivaroxaban in
plasma were measured before and after administration of andexanet or placebo on study day 4. (A) Data from participants in the apixaban study who received andexanet, as a 400-mg
intravenous bolus, or placebo. (B) Participants in the rivaroxaban study who received andexanet, as an 800-mg intravenous bolus, or placebo. (C) Participants in the apixaban study who
received andexanet, as a 400-mg intravenous bolus plus a 4-mg-per minute infusion for 120 minutes, or placebo. (D) Participants in the rivaroxaban study who received andexanet, an
800-mg intravenous bolus plus an 8-mg-per minute infusion for 120 minutes, or placebo. The dashed horizontal line represents the calculated no-effect level for anticoagulant activity
(3.5 ng/mL of apixaban and 4.0 ng/mL of rivaroxaban). The points on the graph represent the mean unbound inhibitor plasma concentrations, and I bars indicate the standard error.
There was a signiﬁcant difference (P b .05) between andexanet and placebo until 2 hours after the end of the bolus and 1 hour after the end of the infusion in the apixaban study and
until 3 hours after the end of the bolus and 3 hours after the end of the infusion in the rivaroxaban study. Reprinted with permission from Massachusetts Medical Society [24].
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cant. Ciraparantag required a 30:1 molar ratio (compared with 1:1
with andexanet), consistentwith the difference inmechanism of action.
2.3. Preclinical human blood in vitro studies
Rivaroxaban or apixaban was added to plasma from healthy human
volunteers at 1 and 2 times the therapeutic maximum concentration
[39]. The effect of ciraparantag on anti-FXa ac-tivity was measured byFig. 3.Molecular structure of ciraparantag. Reprina chromogenic assay, and rivarox-aban and apixaban anti-FXa activity
were completely reversed in a dose-dependent manner.
2.4. Clinical studies
Forty healthy subjectswere given enoxaparin 1.5mg/kg, and 4hours
later they received placebo or 100 mg, 200 mg, or 300 mg of
ciraparantag, and whole blood clotting times were measured [43]. Of
note, enoxaparin increased whole blood clotting time by 28.5% ±ted with permission from Ansell et al. [44].
Table 3
Summary of Preclinical and Clinical Studies of Ciraparantag.
Enoxaparin Dabigatran Rivaroxaban Apixaban Edoxaban
Animal in vivo
Rat tail transection – Decreased bleeding
by N90% [39]
Decreased bleeding by N90% [39] Decreased bleeding by N90% [39] Decreased bleeding [45,48]
Rat liver laceration – – – – Decreased bleeding, reversed
change inWBCT, and normalized
clot ﬁbrin diameter [45,46]
Rabbit liver laceration – – – – Decreased bleeding by up to
76% [47]
Human in vitro – – Dose-dependent reversal of
anti-FXa levels in spiked
plasma [39,48]
Dose-dependent reversal of
anti-FXa levels in spiked
plasma [39,48]
–
Human in vivo Increase in WBCT reversed
within 5 min [43]
– – – Dose-dependent reversal of
increase in WBCT [44]
No procoagulation
detected by D-dimer,
F1.2, or TFPI [43]
F1.2 = prothrombin fragments 1 and 2; FXa = factor Xa; TFPI = tissue factor pathway inhibitor; WBCT= whole blood clotting time.
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clotting timewithin 20minutes in subjects receiving 100mgandwithin
5 minutes with the 200-mg dose, and the effect was sustained for
24 hours. There was no signal for hypercoagulability as measured by
D-dimer, F1.2, or tissue factor pathway inhibitor.
In a dose-escalation study, 80 healthy volunteerswere divided into 8
cohorts, eachwith a different dose (5, 15, 25 [2 cohorts], 50, 100, 200, or
300 mg of ciraparantag) [44]. All patients received 60 mg of edoxaban
and were randomized in an 8:2 ratio to ciraparantag or placebo 3
hours after edoxaban administration. Edoxaban increased whole blood
clotting time by 37% over baseline, and ciraparantag 100 mg and
300 mg reduced this to within 10% of baseline within 10 minutes, and
the effect persisted for 24 hours (Fig. 4). Subjects receiving placebo re-
quired approximately 12 to 15 hours to decrease whole blood clotting
times to within 10% of baseline. Mean ﬁbrineﬁber diameter was deter-
mined from analyzing scanning electron micrographs of clots using a
computer algorithm (Fig. 5). Edoxaban decreased the mean ﬁbrineﬁber
diameter from approximately 250 nm to 125 nm, and the diameter was
restored within 30 minutes of ciraparantag doses that had been shown
to reverse elevation in whole blood clotting times. There was noPER977
administered

















































Fig. 4.Effect of PER977 (ciraparantag) onwhole-blood clotting time. Shownare themeanwhole
3 hours later by a single intravenous dose of 25 mg, 100 mg, or 300 mg PER977 (ciraparantag)evidence of hypercoagulability as measured by changes in D-dimer,
F1.2, tissue factor pathway inhibitor, or whole blood clotting time. Po-
tentially ciraparantag-related adverse reactions included transient
mild perioral and facial ﬂushing, dysgeusia, and headache. One subject
hadmoderatemuscle cramping and elevated post-treatment creatinine
phosphokinase levels, but these events were not considered to be relat-
ed to the study drug.
Ciraparantag is being developed as a “universal” anticoagulant re-
versal agent to block the anticoagulant effect of unfractionated heparin,
LMWH, fondaparinux, and the new direct oral anticoagulants (Table 1),
and the FDA has granted fast-track designation to its development [49].
3. Conclusions
At the present time, there are no speciﬁc reversal agents available
for the direct oral FXa inhibitors. Emerging data from early-phase
studies of andexanet alfa and ciraparantag are encouraging, and phase
3 studies in patients who require reversal for signiﬁcant bleeding or ur-
gent invasive procedure/surgery are eagerly anticipated. Approximately





*P < .05 vs placebo
istration
18 21 24 27
blood clotting times after administration of a single oral 60-mg dose of edoxaban, followed
or placebo. Reprinted with permission from Massachusetts Medical Society [44].
Fig. 5. Dose-dependent normalization of ﬁbrin diameter with ciraparantag (PER977) in human volunteers treated with edoxaban. Top: Clot ﬁbrin structure pre- and post-ciraparantag
(upper and lower photographs represent lower and higher magniﬁcation). Bottom: Computer algorithm-based quantiﬁcation of clot ﬁbrin diameter. IV = intravenous; PO = oral.
Reprinted with permission from Massachusetts Medical Society [44].
44 T.J. Milling Jr, S. Kaatz / American Journal of Emergency Medicine 34 (2016) 39–45demonstrating the efﬁcacy and safety of a rapid onset reversal agent for
warfarin. Current developments are encouraging that patients taking
oral anti-FXa anticoagulants will not have to wait as long.
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